ZA200906899B - Process for preparation of erlotinib and its pharmaceutically acceptable salts - Google Patents
Process for preparation of erlotinib and its pharmaceutically acceptable saltsInfo
- Publication number
- ZA200906899B ZA200906899B ZA200906899A ZA200906899A ZA200906899B ZA 200906899 B ZA200906899 B ZA 200906899B ZA 200906899 A ZA200906899 A ZA 200906899A ZA 200906899 A ZA200906899 A ZA 200906899A ZA 200906899 B ZA200906899 B ZA 200906899B
- Authority
- ZA
- South Africa
- Prior art keywords
- erlotinib
- preparation
- pharmaceutically acceptable
- acceptable salts
- salts
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN681MU2007 | 2007-04-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200906899B true ZA200906899B (en) | 2010-05-26 |
Family
ID=39580101
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200906899A ZA200906899B (en) | 2007-04-04 | 2009-01-01 | Process for preparation of erlotinib and its pharmaceutically acceptable salts |
Country Status (9)
Country | Link |
---|---|
US (2) | US8642758B2 (ko) |
EP (1) | EP2139868B1 (ko) |
JP (2) | JP5524041B2 (ko) |
KR (2) | KR20140069232A (ko) |
AU (1) | AU2008235274B2 (ko) |
CA (1) | CA2682013C (ko) |
NZ (1) | NZ579997A (ko) |
WO (1) | WO2008122776A2 (ko) |
ZA (1) | ZA200906899B (ko) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2682013C (en) | 2007-04-04 | 2015-06-30 | Cipla Limited | Process for preparation of erlotinib and its pharmaceutically acceptable salts |
EP2162444B1 (en) | 2007-07-11 | 2014-06-04 | Hetero Drugs Limited | An improved process for the preparation of erlotinib hydrochloride |
WO2010040212A1 (en) * | 2008-10-08 | 2010-04-15 | Apotex Pharmachem Inc. | Processes for the preparation of erlotinib hydrochloride |
CN101735156B (zh) * | 2008-11-20 | 2012-07-04 | 上海医药工业研究院 | 厄罗替尼盐酸盐的多晶型l、其制备方法及其应用 |
CN102438995B (zh) | 2009-03-26 | 2014-12-17 | 兰贝克赛实验室有限公司 | 厄洛替尼或其药学上可接受的盐的制备工艺 |
CN101863844B (zh) * | 2009-04-16 | 2012-10-03 | 欧美嘉股份有限公司 | 6,7-取代基-4-苯胺类喹唑啉的合成方法 |
CN102746242A (zh) * | 2009-04-16 | 2012-10-24 | 欧美嘉股份有限公司 | 6,7-取代基-4-苯胺类喹唑啉的合成方法 |
WO2011058525A2 (en) | 2009-11-12 | 2011-05-19 | Ranbaxy Laboratories Limited | Processes for the preparation of erlotinib hydrochloride form a and erlotinib hydrochloride form b |
WO2011068403A2 (en) * | 2009-12-02 | 2011-06-09 | Ultimorphix Technologies B.V. | Novel n-{3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamjne salts |
EP2348020A1 (en) | 2009-12-23 | 2011-07-27 | Esteve Química, S.A. | Preparation process of erlotinib |
WO2011147102A1 (zh) * | 2010-05-28 | 2011-12-01 | 翔真生物科技股份有限公司 | 6,7-取代基-4-苯胺类喹唑啉的合成方法 |
US8952022B2 (en) | 2010-07-23 | 2015-02-10 | Generics [Uk] Limited | Pure erlotinib |
CN101891691A (zh) * | 2010-07-30 | 2010-11-24 | 天津市炜杰科技有限公司 | 一种盐酸埃罗替尼的制备方法 |
KR20130136465A (ko) * | 2010-10-22 | 2013-12-12 | 커먼웰쓰 사이언티픽 앤드 인더스트리얼 리서치 오가니제이션 | 유기 전계발광 소자 |
CN102863395A (zh) * | 2011-07-04 | 2013-01-09 | 北京六盛合医药科技有限公司 | 一种厄洛替尼的合成新方法 |
HU230483B1 (hu) | 2011-10-10 | 2016-07-28 | Egis Gyógyszergyár Nyrt. | Erlotinib sók |
CN102827087B (zh) * | 2012-06-18 | 2015-03-25 | 中国科学院成都生物研究所 | 一种厄洛替尼的合成方法 |
US9593083B2 (en) | 2012-09-04 | 2017-03-14 | Shilpa Medicare Limited | Crystalline erlotinib hydrochloride process |
CN103772298A (zh) * | 2012-10-25 | 2014-05-07 | 鲁南制药集团股份有限公司 | 一种盐酸厄罗替尼多晶型物及其制备方法 |
WO2014118737A1 (en) | 2013-01-31 | 2014-08-07 | Ranbaxy Laboratories Limited | Erlotinib salts |
CN103275020A (zh) * | 2013-05-06 | 2013-09-04 | 苏州立新制药有限公司 | 厄洛替尼的制备方法 |
CN103709110B (zh) * | 2013-12-13 | 2016-05-04 | 浙江普洛康裕制药有限公司 | 一种盐酸厄洛替尼关键中间体的制备方法 |
CN103980207B (zh) * | 2014-04-04 | 2016-03-09 | 亿腾药业(泰州)有限公司 | 一种盐酸厄洛替尼b型晶的合成方法 |
CN104250230A (zh) * | 2014-09-05 | 2014-12-31 | 亿腾药业(泰州)有限公司 | 厄洛替尼柠檬酸盐与其晶型以及它们的制备方法 |
CN104725327B (zh) * | 2015-03-03 | 2017-08-25 | 山东大学 | 一种盐酸厄洛替尼的环保制备方法 |
CN107655983B (zh) * | 2016-07-25 | 2021-08-27 | 重庆华邦胜凯制药有限公司 | 盐酸厄洛替尼的关键起始原料三乙炔苯胺中潜在基因毒性杂质的分离与测定方法 |
CN106928069B (zh) * | 2017-03-21 | 2019-03-19 | 上海玉函化工有限公司 | 一种4,5-二(2-甲氧基乙氧基)-2-硝基苯甲酸乙酯的制备方法 |
CN108358798A (zh) * | 2018-02-12 | 2018-08-03 | 黑龙江鑫创生物科技开发有限公司 | 一种微通道反应器合成厄洛替尼中间体的方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK159079A (da) * | 1978-05-18 | 1979-11-19 | Pfizer | Fremgangsmaade til fremstilling af derivater af 4-amino-2-piperidinoquinazolin eller syreadditionssalte deraf |
JP3088018B2 (ja) | 1995-03-30 | 2000-09-18 | ファイザー・インコーポレーテッド | キナゾリン誘導体 |
US5747498A (en) * | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
EP1076652B1 (en) * | 1998-04-29 | 2005-05-18 | OSI Pharmaceuticals, Inc. | N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate |
YU13200A (sh) | 1999-03-31 | 2002-10-18 | Pfizer Products Inc. | Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja |
UA74803C2 (uk) * | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування |
US7148231B2 (en) * | 2003-02-17 | 2006-12-12 | Hoffmann-La Roche Inc. | [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph |
CA2682013C (en) | 2007-04-04 | 2015-06-30 | Cipla Limited | Process for preparation of erlotinib and its pharmaceutically acceptable salts |
-
2008
- 2008-04-03 CA CA2682013A patent/CA2682013C/en not_active Expired - Fee Related
- 2008-04-03 WO PCT/GB2008/001186 patent/WO2008122776A2/en active Application Filing
- 2008-04-03 AU AU2008235274A patent/AU2008235274B2/en not_active Ceased
- 2008-04-03 US US12/593,212 patent/US8642758B2/en not_active Expired - Fee Related
- 2008-04-03 KR KR1020147010793A patent/KR20140069232A/ko not_active Application Discontinuation
- 2008-04-03 KR KR1020097022954A patent/KR101441930B1/ko not_active IP Right Cessation
- 2008-04-03 JP JP2010501588A patent/JP5524041B2/ja not_active Expired - Fee Related
- 2008-04-03 NZ NZ579997A patent/NZ579997A/xx not_active IP Right Cessation
- 2008-04-03 EP EP08718987.4A patent/EP2139868B1/en not_active Not-in-force
-
2009
- 2009-01-01 ZA ZA200906899A patent/ZA200906899B/xx unknown
-
2014
- 2014-01-13 US US14/153,594 patent/US20140194624A1/en not_active Abandoned
- 2014-02-03 JP JP2014018797A patent/JP2014129362A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2682013A1 (en) | 2008-10-16 |
KR20100017095A (ko) | 2010-02-16 |
US20100094004A1 (en) | 2010-04-15 |
JP2014129362A (ja) | 2014-07-10 |
JP2010523535A (ja) | 2010-07-15 |
WO2008122776A2 (en) | 2008-10-16 |
CA2682013C (en) | 2015-06-30 |
KR101441930B1 (ko) | 2014-09-19 |
AU2008235274B2 (en) | 2013-04-18 |
EP2139868A2 (en) | 2010-01-06 |
JP5524041B2 (ja) | 2014-06-18 |
KR20140069232A (ko) | 2014-06-09 |
NZ579997A (en) | 2012-08-31 |
US8642758B2 (en) | 2014-02-04 |
WO2008122776A3 (en) | 2009-03-26 |
US20140194624A1 (en) | 2014-07-10 |
AU2008235274A1 (en) | 2008-10-16 |
EP2139868B1 (en) | 2015-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200906899B (en) | Process for preparation of erlotinib and its pharmaceutically acceptable salts | |
IL206500A0 (en) | Process for the preparation of sitagliptin and pharmaceutically acceptable salts thereof | |
SI2086945T1 (sl) | Novi postopek za pripravo statinov in njihovih farmacevtsko sprejemljivih soli | |
EP2499147A4 (en) | IMPROVED METHODS FOR THE PRODUCTION OF PRASUGREL AND PHARMACEUTICAL ACCEPTABLE SALTS THEREOF | |
HRP20150477T1 (en) | Methods of preparing quinazolinone derivatives | |
PL2362875T3 (pl) | Proces do wytwarzania alfa-tokotrienolu i pochodnych | |
SI1981863T1 (sl) | Postopek za pripravo aminokrotonilamino-substituiranih kinazolinskih derivatov | |
IL198847A0 (en) | New process for the preparation of 2-imino-thiazolidin-4-one derivatives | |
ZA200806799B (en) | Novel pyrone-indole derivatives and process for their preparation | |
PT2170844T (pt) | Novos polimorfos de cloridrato de erlotinib e método de preparação | |
EP2069329A4 (en) | PROCESS FOR THE PREPARATION OF BENZIMIDAZOLE DERIVATIVES AND THEIR SALTS | |
SI2400954T1 (sl) | Postopek za pripravo trdne oralne dozirne oblike solifenacina in njegovih farmacevtsko sprejemljivih soli | |
EP2038282A4 (en) | SALTS OF PYRROLOPYRIMIDINONE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | |
GB0606234D0 (en) | Pharmaceutically acceptable salts and polymorphic forms | |
EP2069307A4 (en) | PROCESS FOR THE PREPARATION OF MONTELUKAST AND ITS SALTS | |
ZA200902575B (en) | Process for the synthesis of clopidogrel and new forms of pharmaceutically acceptable salts thereof | |
IL205082A0 (en) | Process for the preparation of tetranorlabdane derivatives | |
PL2291374T3 (pl) | Sposób wytwarzania solifenacyny i/lub jej farmaceutycznie dopuszczalnych soli o wysokiej czystości farmaceutycznej | |
PT2170920E (pt) | Sais estáveis de s-adenosilmetionina e processo para a sua preparação. | |
HUP0700756A2 (en) | Process for the preparation of pharmaceutical intermediers | |
EP2121729A4 (en) | PHARMACEUTICAL, SUBSTANTIVE SALTS OF THYMODEPRESSINE AND METHOD FOR THE PRODUCTION THEREOF | |
ZA201000802B (en) | Process for the preparation of alfuzosin hydrochloride | |
HK1129687A1 (en) | A process for the preparation of poly-alfa-glutamic acid and derivatives thereof | |
PT2419407E (pt) | Processo melhorado para a preparação de fluvastatina e dos seus sais | |
GB0605344D0 (en) | Pharmaceutically acceptable salts and polymorphic forms |